Streamlining Medicaid Skyrizi Prior Authorization Workflows

Efficiently managing Medicaid Skyrizi prior authorization is critical for timely patient access to this essential IL-23 inhibitor. Klivira streamlines the complex, state-specific requirements across Fee-for-Service (FFS) and Managed Care Organization (MCO) models.

For revenue cycle directors and prior authorization coordinators, navigating the varied landscape of Medicaid requirements for specialty drugs like Skyrizi (risankizumab) presents significant operational challenges. Each state, and often each Medicaid MCO, maintains distinct criteria and submission pathways, directly impacting approval turnaround times and resource allocation. Understanding these nuances is key to optimizing patient care and financial performance.

Understanding Skyrizi and Medicaid's PA Framework

Skyrizi (risankizumab) is an IL-23 inhibitor indicated for conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a high-cost specialty medication, Skyrizi typically requires prior authorization from Medicaid payers to ensure medical necessity. Medicaid's decentralized structure, with state-by-state variations and the prevalence of Managed Care Organizations (MCOs), introduces a layer of complexity to the PA process for such medications.

Medicaid Delivery Models and PA Impact

Medicaid benefits are delivered primarily through two models: Fee-for-Service (FFS), where the state agency directly manages benefits, and Medicaid Managed Care, where states contract with MCOs (e.g., Centene subsidiaries, Molina, UHC Community Plan, Anthem Medicaid plans) to administer care. Most states employ a mixed model. For Skyrizi, this means PA requests may route either to the state Medicaid agency's fiscal agent for FFS members or to the responsible MCO for managed care enrollees, each with potentially different portals and workflows.

Key Channels for Medicaid Skyrizi Prior Authorization Submission

**State Medicaid Portals:** Used for Fee-for-Service (FFS) submissions, directly interfacing with the state Medicaid agency.
**MCO Provider Portals:** Each Medicaid Managed Care Organization typically maintains its own proprietary provider portal for PA submissions.
**X12 278 Transactions:** Where supported by the state or MCO, electronic submission via the X12 278 standard offers a structured data exchange pathway.
**Fax/Phone:** Traditional channels remain available, though often less efficient for high-volume specialty drug PAs.

Navigating Skyrizi Medical Necessity Criteria and Policies

Medicaid's medical necessity criteria for Skyrizi are state-specific, published by the respective state Medicaid agency's policy library. While MCOs administer benefits, they cannot impose criteria more restrictive than the state Medicaid program itself. These policies often include requirements such as diagnosis confirmation, prior therapy failures (step therapy), and specific dosing or quantity limits. For dual-eligible Medicare and Medicaid members, applicable National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs) found in the CMS Medicare Coverage Database may also be relevant.

Klivira's Approach to Medicaid Skyrizi PA Automation

Klivira's platform is engineered to navigate the intricate landscape of Medicaid prior authorization for specialty drugs like Skyrizi. Our system intelligently identifies the responsible Medicaid delivery model (FFS vs. managed care) and the specific MCO, applying the correct state-level or MCO-specific criteria. This includes coordinating for dual-eligible Medicare and Medicaid (D-SNP) members, ensuring that PA requests are accurately routed and processed against the appropriate policy floor.

CMS-0057-F Implications for Medicaid PA

The CMS-0057-F final rule significantly impacts Medicaid Managed Care Organizations, designating them as impacted payers. This mandates adherence to specific prior authorization decision timeframes (72-hour standard, 24-hour expedited) and the future implementation of FHIR-based Prior Authorization APIs. While traditional FFS Medicaid is less directly affected by the API requirements, the broader push for interoperability under this rule will influence PA processing across the Medicaid ecosystem, aiming for greater transparency and efficiency in obtaining approvals for drugs like Skyrizi.

Frequently asked questions

What is Skyrizi and why does Medicaid require prior authorization for it?

Skyrizi (risankizumab) is an IL-23 inhibitor used to treat conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a high-cost specialty medication, Medicaid requires prior authorization to verify medical necessity, ensure appropriate use, and manage costs, aligning with state-specific formulary and utilization management guidelines.

How do Medicaid's FFS and Managed Care models affect Skyrizi prior authorization?

Under Fee-for-Service (FFS), Skyrizi PA requests are submitted directly to the state Medicaid agency or its fiscal agent. For Medicaid Managed Care, PA requests are routed to the specific Managed Care Organization (MCO) responsible for the member's benefits, each with its own portal and criteria. Klivira identifies the correct pathway, streamlining submissions regardless of the model.

Where can I find Medicaid's specific PA criteria for Skyrizi?

Specific prior authorization criteria for Skyrizi are published by each state's Medicaid agency in their official policy library. For members enrolled in a Medicaid MCO, the MCO's provider portal or policy documents will outline their specific requirements, which must adhere to the state's baseline criteria. Klivira's platform integrates these diverse policy sources to inform PA submissions.

What are the common channels for submitting Skyrizi prior authorization to Medicaid?

Common channels include state Medicaid agency online portals for FFS plans, individual MCO provider portals for managed care plans, and electronic submission via X12 278 where supported. Traditional methods like fax or phone may also be used but are generally less efficient. Klivira automates routing across these channels.

How does CMS-0057-F impact Skyrizi prior authorization for Medicaid members?

CMS-0057-F directly impacts Medicaid Managed Care Organizations, mandating specific PA decision timeframes (72-hour standard, 24-hour expedited) and requiring the implementation of FHIR-based Prior Authorization APIs by phased deadlines. This aims to improve the efficiency and transparency of PA processes for specialty drugs like Skyrizi, reducing administrative burden for providers and ensuring timely access for patients.